Table 1.

Summary of patients’ characteristics, treatment and outcome

Patient	Site	Age at COVID-19	Gender	MM subtype	High-risk cytogenetics*	Prior lines of therapy	Pretreatment	Current therapy	EMD	Time since MM diagnosis, months	Date of COVID-19 diagnosis	COVID-19 symptoms	Pulmonary infiltration	CRP, mg/l	PCT, ng/ml	COVID treatment	ICU admission	Mechanical ventilation	Circulatory support	Survival status at discharge	Retreatment after COVID-19	COVID-19 antibody after recovery
1	Würzburg	53	Male	IgG	No	2	PI, IMiD, ASCT, DARA	DRD	None	142	11.04.2020	Cough, fever	Yes	50	0.10	IVAB,HCQ	No	No	No	Alive	No	IgG positive
2	Würzburg	50	Male	IgG	Yes	1	PI, IMiD, ASCT	Lenalidomide maintenance	None	22	14.03.2020	Cough, fever, myalgia	Yes	40	0.10	None	No	No	No	Alive	Lenalidomide maintenance	IgG positive
3	Würzburg	70	Male	IgG	No	2	PI, IMiD, ASCT, DARA	DARA-VRD	None	58	16.04.2020	Asymptomatic	No	10	0.08	None	No	No	No	Alive	No	IgG, IgM negative
4	Würzburg	83	Female	IgG	No	4	PI, IMiD, DARA	DVD	None	94	23.04.2020	Asymptomatic	Yes	48	0.10	IVAB	No	No	No	Alive	No	NA
5	Würzburg	79	Female	IgA	No	0	None	n.a.	None	NA	01.04.2020	Nausea	No	29	0.05	None	No	No	No	Alive	DARA-VRCD	IgG positive
6	Wuhan	39	Male	LC	NA	4	PI, IMiD	S/P CAR-T apheresis	CNS, pleura, lung, para-medullary lesion	30	17.02.2020	Cough, fever, vomiting, seizure	Yes	13	0.21	IVAB	Yes	Yes	Yes	Alive	CAR-T in preparation	IgG, IgM negative
7	Wuhan	53	Female	IgA	NA	1	PI, IMiD	VTD	Para-medullary lesion	3	25.01.2020	Fever, fatigue	Yes	106	30.05	IVAB, arbidol, IFN-α, oseltamivir	Yes	Yes	Yes	Dead	NA	NA
8	Wuhan	61	Male	IgG	NA	0	None	n.a.	None	NA	23.01.2020	Chest pain	Yes	108	0.07	IVAB, arbidol, IFN-α, oseltamivir	No	No	No	Alive	NA	NA

CAR-T, chimeric antigen receptor T-cells; ASCT, autologous stem cell transplant; CNS - central nervous system; CRP, C-reactive protein; DARA, daratumumab; DARA-VRD, daratumumab, bortezomib, lenalidomide, dexamethasone; DARA-VRCD, daratumumab, bortezomib, lenalidomide, cyclophosphamide, dexamethasone; DRD, daratumumab, lenalidomide, dexamethasone; DVD, daratumumab, bortezomib, dexamethasone; EMD, extramedullary disease; HCQ, hydroxychloroquine; ICU, intensive care unit; IFN-α, interferon-α; Ig - immunoglobulin; IMiD, immunomodulatory drug; IVAB, intravenous antibiotics; LC, light chain; MM, multiple myeloma; NA, not available; PCT, procalcitonin; PI, proteasome inhibitor; VTD, bortezomib, thalidomide, dexamethasone; *at least one of the following: t(4;14), t(14;16), del(17p)